^
4ms
New P1 trial
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BRCA (Breast cancer early onset)
|
YSCH-01
6ms
Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial. (PubMed, J Immunother Cancer)
The study shows that YSCH-01 injections were safe and well tolerated and exhibited preliminary efficacy in patients with advanced solid tumors, supporting further investigation to evaluate its efficacy and safety.
Journal • Metastases
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6)
|
YSCH-01
1year
Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma. (PubMed, Neurooncol Adv)
Furthermore, we employed a patient-derived xenograft model of recurrent glioblastoma to test the effectiveness of YSCH-01 against temozolomide. Our initial findings confirm that a double-modified oncolytic adenovirus armed with a recombinant interferon-like gene is both safe and effective in the treatment of malignant glioma. Furthermore, when utilized in combination with a targeted therapy gene strategy, these oAds exhibit a more profound effect in tumor therapy and an enhanced ability to inhibit tumor growth at remote sites.
Journal • Oncolytic virus
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
temozolomide • YSCH-01
over1year
YSCH-01: Safety and Tolerability Study of Recombinant L-IFN Adenovirus Injection in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
P1, N=6, Recruiting, Binhai Hospital of Fujian Medical University | Not yet recruiting --> Recruiting
Enrollment open
|
YSCH-01
over1year
New P1 trial
|
YSCH-01